BridgeMD
New treatment option for Prediabetes
Official title Effects of Exogenous Ketones on Cognitive Function in Older Adults With Prediabetes?
ClinicalTrials.gov ID: NCT07546409
What this study is testing
- What it's testing
- Brief Summary The goal of this clinical trial is to learn whether older adults with prediabetes, but no diagnosed cognitive impairment, show early changes in brain energy use and thinking speed compared to older adults with normal blood sugar levels. The study will also test whether a single dose of an exogenous ketone supplement can improve brain energy use and cognitive processing speed.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 60 to 75. Healthy volunteers may be eligible.
You may be able to join if
- Age 60 to 75 years
- Able to provide written informed consent
- Fluent in English
- No diagnosed cognitive impairment or dementia Classified as either:
- Prediabetes (based on American Diabetes Association criteria), or Normal glucose regulation (control group)
You likely can't join if
- Diagnosis of mild cognitive impairment, dementia, or other neurodegenerative disorder
- Diagnosis of type 1 diabetes or type 2 diabetes
- Use of glucose-lowering medications (e.g., insulin, metformin, glucagon-like peptide-1 receptor agonists)
- History of major neurological disorder (e.g., stroke, traumatic brain injury with loss of consciousness \>30 minutes, epilepsy, multiple sclerosis)
- Major psychiatric disorder not stable on treatment
- Uncontrolled hypertension or significant cardiovascular disease
See the full eligibility criteria
- Age 60 to 75 years
- Able to provide written informed consent
- Fluent in English
- No diagnosed cognitive impairment or dementia Classified as either:
- Prediabetes (based on American Diabetes Association criteria), or Normal glucose regulation (control group)
- Medically stable and cleared to undergo positron emission tomography and magnetic resonance imaging
- Willing to comply with study procedures, including metabolic testing, supplement ingestion, and neuroimaging
- Diagnosis of mild cognitive impairment, dementia, or other neurodegenerative disorder
- Diagnosis of type 1 diabetes or type 2 diabetes
- Use of glucose-lowering medications (e.g., insulin, metformin, glucagon-like peptide-1 receptor agonists)
- History of major neurological disorder (e.g., stroke, traumatic brain injury with loss of consciousness \>30 minutes, epilepsy, multiple sclerosis)
- Major psychiatric disorder not stable on treatment
- Uncontrolled hypertension or significant cardiovascular disease
- Severe renal, hepatic, or gastrointestinal disease that may affect supplement metabolism
- Contraindications to magnetic resonance imaging (e.g., non-compatible implanted devices, severe claustrophobia)
The study team makes the final eligibility decision.
Where it's taking place
- Birmingham, Alabama, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 60 years to 75 years. Healthy volunteers may be eligible. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Birmingham, Alabama, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.